Processa Pharmaceuticals, Inc.
PCSA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001533743
In the last 90 days, Processa Pharmaceuticals, Inc. insiders filed 5 open-market purchases and 0 sales; 12 institutions reported holding it in 13F filings for Q2 2026, worth $498.3K in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Processa Pharmaceuticals, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- +1 vs. Q2 2025
- Shares held
- 1.78M
- +1.41M (+377.9%) vs. Q2 2025
- Total value
- $341.9K
- +$266.0K (+350.4%) vs. Q2 2025
- New holders
- 7
- 3 more added
- Sold out
- 6
- 2 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PCSA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 12 | $498.3K |
| Q1 2026 | 10 | $448.5K |
| Q4 2025 | 10 | $331.0K |
| Q3 2025 | 14 | $341.9K |
| Q2 2025 | 13 | $75.9K |
| Q1 2025 | 9 | $63.2K |
| Q4 2024 | 8 | $87.5K |
| Q3 2024 | 8 | $66.5K |
| Q2 2024 | 9 | $101.0K |
| Q1 2024 | 11 | $251.5K |
| Q4 2023 | 18 | $376.5K |
| Q3 2023 | 20 | $349.8K |
| Q2 2023 | 19 | $691.4K |
| Q1 2023 | 22 | $852.6K |
| Q4 2022 | 18 | $1.28M |
| Q3 2022 | 18 | $2.58M |
| Q2 2022 | 18 | $3.24M |
| Q1 2022 | 18 | $3.22M |
| Q4 2021 | 19 | $6.47M |
| Q3 2021 | 18 | $12.2M |
| Q2 2021 | 18 | $11.2M |
| Q1 2021 | 17 | $12.3M |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Processa Pharmaceuticals, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Advisor Group Holdings, Inc. | 2 | $0 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 154 | $30 | 0.00% | 00.0% | Unchanged |
| Jones Financial Companies LLLP | 188 | $40 | 0.00% | +188 | New |
| Bank of America Corp | 378 | $72 | 0.00% | +270+250.0% | Added |
| Tower Research Capital LLC (TRC) | 2,393 | $459 | 0.00% | −69−2.8% | Reduced |
| Miracle Mile Advisors, LLC | 10,000 | $1.92K | 0.00% | +10,000 | New |
| Sassicaia Capital Advisers LLC | 15,977 | $3.07K | 0.00% | +15,977 | New |
| StoneX Group Inc. | 18,951 | $3.64K | 0.00% | +18,951 | New |
| Citigroup Inc | 34,051 | $6.53K | 0.00% | +34,051 | New |
| Two Sigma Securities, LLC | 36,248 | $6.96K | 0.00% | +36,248 | New |
| Virtu Financial LLC | 40,843 | $8.00K | 0.00% | −63,880−61.0% | Reduced |
| Vanguard Group Inc | 288,212 | $55.3K | 0.00% | +263,779+1,079.6% | Added |
| Geode Capital Management, LLC | 303,304 | $58.2K | 0.00% | +252,731+499.7% | Added |
| Stonepine Capital Management, LLC | 1,030,200 | $197.7K | 0.16% | +1,030,200 | New |
| UBS Group AG | 0 | $0 | 0.00% | −64,612−100.0% | Sold out |
| Alpine Global Management, LLC | 0 | $0 | 0.00% | −53,416−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −41,848−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −19,270−100.0% | Sold out |
| Sequoia Financial Advisors, LLC | 0 | $0 | 0.00% | −11,000−100.0% | Sold out |
| SBI Securities Co., Ltd. | 0 | $0 | 0.00% | −12−100.0% | Sold out |